A detailed history of Freestone Grove Partners LP transactions in Biogen Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 218,866 shares of BIIB stock, worth $36.7 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
218,866
Previous 111,004 97.17%
Holding current value
$36.7 Million
Previous $13.9 Billion 119.92%
% of portfolio
0.23%
Previous 0.11%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$122.68 - $148.84 $13.2 Million - $16.1 Million
107,862 Added 97.17%
218,866 $30.7 Billion
Q2 2025

Aug 14, 2025

BUY
$113.38 - $135.49 $12.6 Million - $15 Million
111,004 New
111,004 $13.9 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $24.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.